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Background: Several treatments for postmenopausal osteoporosis have been available in the 
past decade, but adherence to these treatments has been judged inadequate. The prevention of 
hip fracture by these medications is still modest.
Methods: A literature search was performed for treatment with zoledronic acid for the preven-
tion of hip fracture.
Results: In the The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly 
(HORIZON) Pivotal Fracture Trial, involving 7765 postmenopausal women with low bone min-
eral density or with prevalent vertebral fracture, women taking zoledronic acid had a 41% relative 
risk reduction for hip fracture, at 3 years, compared to placebo. In the HORIZON Recurrent 
Fracture Trial, 2127 patients (76% were women) were randomized to receive either zoledronic 
acid or placebo after sustaining a ﬁ  rst hip fracture. A reduction of 30% in the second hip fracture 
risk was observed, but it did not reach statistical signiﬁ  cance. Zoledronic acid was generally safe 
in these trials, although a slightly increased rate of severe atrial ﬁ  brillations was observed in the 
HORIZON Prevention Fracture Trial, but not in the HORIZON Recurrent Fracture Trial.
Conclusion: Yearly zoledronic acid reduces the risk of hip fracture, both in postmenopausal 
osteoporotic women with and without prevalent vertebral fracture and in men and women with 
a recent ﬁ  rst hip fracture.
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Introduction
Hip fracture is the most devastating complication due to bone fragility. Mortality is 
increased in women with hip fracture, 10% to 20% higher than expected for their age 
within the ﬁ  rst year1,2 and this excess mortality persists for several years after hip fracture.3,4 
Loss of independence and entry in nursing homes are also common consequences of hip 
fractures.5 Prevention of hip fracture, however, is challenging because one needs to target 
both the bone – with anti-osteoporosis agents – and the triggering event that is generally a 
fall from standing height. In addition, hip fracture occurs mostly in individual over 75 years 
of age,6 and the mean age at hip fracture is currently increasing.7,8 The second hip fracture 
is not a rare event, with an estimated incidence of around 2% per year.9,10 Elderly patients 
with hip fracture often present with several comorbidities hampering pharmacologic treat-
ment because of drug interaction, and a negative inﬂ  uence on drug persistence. Cognitive 
impairment may also have a negative impact on drug persistence.
Preventing falls has proven to be difﬁ  cult, although some studies suggest that 
vitamin D supplements,11 certain types of exercise, including tai chi,12 and cataract 
surgery13 might reduce the risk of fall. Limiting the consequences of the fall may 
be possible with hip protectors, but their effectiveness has never been convincingly 
established, mainly due to poor compliance.14
A reduction in the incidence of hip fracture has been observed in some trials test-
ing the efﬁ  cacy of oral alendronate and risedronate,15–17 but the magnitude of fracture Therapeutics and Clinical Risk Management 2009:5 170
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risk reduction was about half of that observed for vertebral 
fracture efﬁ  cacy. For the other drugs the evidence is less 
compelling. In the BONE trial, examining the effect of iban-
dronate on fracture risk, no efﬁ  cacy on hip fracture events 
could be obtained in the primary intent to treat analysis.18 
With teriparatide, a 50% reduction in non-vertebral fracture 
risk was shown, but the hip fracture risk reduction was not 
signiﬁ  cant. This latter result may stem from the study design, 
as women were too young to have a sizeable hip fracture 
incidence.19 With intact parathyroid hormone, no efﬁ  cacy 
on non-vertebral fracture, and hip fracture speciﬁ  cally, 
was observed either.20 Although treatment with strontium 
ranelate has been able to diminish the rate of non-vertebral 
fracture by 16%, it is only in a post-hoc analysis that a 33% 
reduction of hip fracture risk could be found in a sub-group 
of women at higher risk of hip fracture.21 No reduction in 
hip fracture risk and all non-vertebral fracture risk has been 
shown with the ﬁ  rst selective estrogen receptor modulator 
(SERM) to be marketed for the treatment of postmenopausal 
osteoporosis, raloxifene.22 With a new, more potent com-
pound, lazofoxifene, it has been shown that a reduction of 
24% in the incidence of non-vertebral fracture risk could be 
obtained, but the 23% reduced risk in hip fracture risk did 
not reach statistical signiﬁ  cance.23
So, there is a clear need for new drugs to improve reduc-
tion in hip fracture risk. These drugs should be adequately 
tolerated in the elderly and their regime should be acceptable 
in those patients who often have many co-prescriptions. In this 
context, we will review the effectiveness of the treatment with 
annual intravenous zoledronic acid to prevent hip fracture.
Methods
Our literature search in PubMed used the following terms: 
zoledronic acid and hip fracture (50 articles), bisphosphonates 
and hip fracture (693 articles). Titles and/or abstracts were 
reviewed to determine the relevance for this review. We have 
selected articles relevant to the prevention of hip fracture with 
zoledronic acid, including all clinical trials and some relevant 
papers on the pharmacology of the compound and some stud-
ies related to the clinical use of bisphosphonates. We have 
also used studies on zoledronic acid we were aware of, which 
had been released only in the form of abstracts at the time of 
preparation of this article.
Pharmacology of zoledronic acid
Zoledronic acid is a potent nitrogen-containing BP, 
which has been widely used in the treatment of Paget’s 
disease of bone, hypercalcemia, multiple myeloma, 
androgen-def iciency-induced bone loss in prostate cancer 
patients, prostate cancer bone metastases, and osteolytic 
bone metastases. This BP has also been marketed more 
recently for the treatment of postmenopausal osteoporosis, 
and should be available soon for the treatment of male 
osteoporosis and of glucocorticoid-induced bone loss.
In rat models, zoledronic acid – administered with sub-
cutaneous injections for 10 days – produces dose-dependent 
increases in cancellous bone volume and connectivity, 
100-times more effectively than pamidronate, and decreases 
bone resorption.24
In another animal model of postmenopausal bone loss – the 
ovariectomized adult rhesus monkey – animals were randomly 
assigned to one control group and four ovariectomy groups. 
The control and one ovariectomized group received saline, 
and the three other ovariectomized groups were given 0.5, 2.5 
or 12.5 μg/kg by a single weekly subcutaneous injection, for 
69 weeks.25 Spine, total body and radius bone mineral den-
sity (BMD) were either preserved or increased by zoledronic 
acid, dose-dependently, up to week 39, and stabilized there-
after. Simultaneously, biochemical markers of bone turnover 
decreased signiﬁ  cantly in monkeys receiving zoledronic acid, 
proportionally to the dosage, and remained reduced until the 
end of the study, compared with animals on placebo.
In a phase II, randomized, double-blind, placebo-controlled 
trial, zoledronic acid or placebo were given intravenously to 
351 postmenopausal women with low BMD (T score   2), 
for 1 year. These patients received placebo or intravenous 
zoledronic acid at doses of 0.25, 0.5 or 1.0 mg every 3 months, 
or 2.0 mg every 6 months, or a single annual 4.0 mg dose.26 
All women received a 1 g per day calcium supplement. All 
zoledronic acid regimens produced similar increases in lum-
bar spine and femoral neck BMD, spanning 4.3% to 5.1% at 
the spine, compared with stable BMD in the placebo group. 
Biochemical markers of bone resorption (urinary N-terminal 
telopeptide of type I collagen [NTX], serum C-terminal telo-
peptide of type I collagen [CTX]) were suppressed during the 
trial, while markers of bone formation were also diminished, 
albeit later after beginning treatment. Post-infusion myalgia 
and transient fever were the most common adverse events.
Two consecutive, open-label extensions of this phase II 
study have been conducted over 5 years.27 In the ﬁ  rst exten-
sion, most patients received 4 mg once a year. They entered 
the second extension thereafter and received either zoledronic 
acid 4 mg per year or calcium alone. Patients were analyzed 
according to the duration of their treatment with zoledronic 
acid (2, 3 or 5 years). Substantial increases in BMD were 
observed in all groups, along with signiﬁ  cant reduction in Therapeutics and Clinical Risk Management 2009:5 171
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biochemical markers of bone turnover. A third of patients, 
however, did not benefit from an optimal reduction in 
bone-speciﬁ  c alkaline phosphatase, even after several zole-
dronic acid infusions. This frequent suboptimal response 
was not observed when examining results of serum CTX-1 
measurements. Taken together, these results may suggest 
that a 4 mg yearly infusion may not have been adequate for 
all these postmenopausal patients.
The one-year phase II trial26 has paved the way for 
conducting a large phase III trial program (the HORIZON 
trials) designed to demonstrate the ability of zoledronic acid 
5 mg once a year given intravenously to reduce osteoporotic 
fracture risk.
Clinical results with zoledronic acid 
in the prevention of hip fracture
Results of two large phase III multicenter randomized 
placebo-controlled trials have been published so far. The 
HORIZON Pivotal Fracture Trial has been conducted among 
postmenopausal osteoporotic women with and without preva-
lent fracture.27 The HORIZON Recurrent Fracture Trial has 
tested the ability of the compound to reduce fracture risk 
among men and women with a recent hip fracture.28
The HORIZON Pivotal Fracture Trial
The Health Outcomes and Reduced Incidence with Zole-
dronic Acid Once Yearly (HORIZON) Pivotal Fracture 
Trial was an international, multicenter, randomized, double-
blind, placebo-controlled trial in postmenopausal women 
with osteoporosis, who were randomly assigned to receive 
either a 15-minute intravenous injection of zoledronic acid 
(5 mg) or placebo, at baseline (day 0), at 12 months, and at 
24 months. All women received oral daily calcium (1000 to 
1500 mg) and vitamin D (400 to 1200 IU) and were moni-
tored for 3 years, to estimate the incidence of new vertebral 
and non-vertebral fracture.
Postmenopausal women between the ages of 65 and 
89 years could be enrolled if they had a BMD T-score 
of −2.5 or less at the femoral neck, with or without preva-
lent vertebral fracture, or a T-score of −1.5 or less, with 
radiological evidence of at least two mild vertebral frac-
tures or one moderate vertebral fracture. Previous use of 
oral bisphosphonates was permitted, the duration of the 
washout period depending on the duration of previous use. 
Concomitant use of several other antiosteoporosis drugs was 
allowed, such as raloxifene, calcitonin, tibolone, tamoxifen, 
dehydroepiandrosterone, ipriﬂ  avone, and medroxyproges-
terone. Patients were stratiﬁ  ed according to these baseline 
osteoporosis therapies. Patients with no bone medication at 
baseline were in stratum 1, whereas those in stratum 2 were 
on an antiosteoporosis drug when they started the trial.
Two primary endpoints were adopted in this trial: the 
incidence of new vertebral fracture in stratum 1 and the 
incidence of hip fracture in both strata 1 and 2. Secondary 
efﬁ  cacy endpoints included any non-vertebral fracture, any 
clinical fracture, and clinical vertebral fracture. Other second-
ary endpoints were changes in BMD at the total hip, femoral 
neck, and lumbar spine, and changes in markers of bone 
resorption (serum C-telopeptide of type I collagen, CTX) 
and formation (bone-speciﬁ  c alkaline phosphatase, BSAP, 
and N-terminal propeptide of type I collagen, PINP).
A total of 7765 women were randomized to receive 
either zoledronic acid (n = 3889) or placebo (n = 3876). 
Their mean age was 73 years, 63% had prevalent vertebral 
fracture and 79% had no other osteoporosis medication at 
baseline (stratum 1). Eighty-four percent of patients were 
still followed-up after 3 years.
The relative risk reduction for hip fracture in women 
taking zoledronic acid was 41% with zoledronic acid and the 
vertebral fracture relative risk reduction at 3 years was 70%. 
Fracture risk reduction after 1 and 2 years of treatment was 
comparable to that observed after 3 years. Non-vertebral frac-
tures were reduced by 25%, all clinical fractures by 33% and 
clinical vertebral by 77%, in women on zoledronic acid.
BMD at the hip increased by 6% and at the spine by 6.7% 
after 3 years of follow-up, compared with the placebo. All 
three markers of bone turnover (serum CTX, BSAP and 
PINP) decreased signiﬁ  cantly compared with the placebo 
group, when they were measured 12 months after starting 
therapy. At 6 and 12 months after each infusion, there was 
no further decline in their concentrations.
The numbers of patients who died, had a serious adverse 
event, or discontinued follow-up because of an adverse 
event did not signiﬁ  cantly differ between the study groups. 
Among patients on zoledronic acid, 31.6% had a brief ﬂ  u-like 
syndrome after the ﬁ  rst infusion, compared with 6.2% in the 
placebo group. A transient increase of more than 0.5 mg/dL 
in serum creatinine levels was observed 9 to 11 days after 
the infusion, among 1.3% of patients with zoledronic acid 
and 0.5% of patients in the placebo group. The number of 
patients who had arrhythmia in the zoledronic acid group 
(266 patients, or 6.9%) was signiﬁ  cantly higher than that in 
the placebo group (203 patients, or 5.3%; p = 0.003), as well 
as serious atrial ﬁ  brillation. In the zoledronic acid group, 
50 patients had serious atrial ﬁ  brillation (1.3%), compared 
with 20 patients (0.5%) in the placebo group. Among these Therapeutics and Clinical Risk Management 2009:5 172
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50 serious atrial ﬁ  brillation events, 47 occurred more than 
30 days after the infusion. The occurrence of stroke, or death 
from stroke, did not differ between the two groups. Two cases 
of potential osteonecrosis of the jaw were identiﬁ  ed (one in 
the placebo group and one in the zoledronic acid group).
In a substudy of the HORIZON fracture trial, 152 patients 
underwent a bone biopsy. Zoledronic acid reduced bone 
turnover by a median 63% and preserved bone structure and 
volume, with evidence of ongoing bone remodeling in 99% of 
the biopsies.30 Bone formation was normal, with no evidence 
of mineralization defect. The concomitant administration of 
other antiosteoporosis drugs did not affect the tissue-level 
response to zoledronic acid.
The HORIZON Recurrent Fracture Trial
The Health Outcomes and Reduced Incidence with Zole-
dronic Acid Once Yearly (HORIZON) Recurrent Fracture 
Trial was an international, multicenter, randomized, placebo-
controlled trial involving men and women with recent hip 
fracture.29 Patients were randomized to receive a yearly 
infusion of either 5 mg of zoledronic acid or an infusion of 
placebo. The treatment was administered within 90 days of 
the surgical repair of the hip fracture, and once a year thereaf-
ter. All patients were supplemented with calcium and a load-
ing dose of vitamin D was administered soon after the ﬁ  rst hip 
fracture. All these patients were unable or unwilling to take 
an oral bisphosphonate. A parallel therapy with calcitonin, a 
SERM, tibolone and hip protectors was authorized.
The primary endpoint was a new clinical fracture. Sec-
ondary endpoints included a second hip fracture and death, as 
well as the change in BMD at the non-fractured hip, and new 
vertebral and non-vertebral fracture. Among 2127 patients, 
1065 received zoledronic acid and 1062 were on placebo, 
and 76% were women.
After a median follow-up of 1.9 years, the observed 
fracture rate of clinical fracture was 8.6% in the zoledronic 
acid group and 13.9% in the placebo group, representing an 
absolute risk reduction of 5.3% and a relative risk reduction 
of 35%. There was also a non-signiﬁ  cant 30% second hip 
fracture relative risk reduction associated with the use of 
zoledronic acid. Death from all causes was reduced by 28% 
in the zoledronic acid group. BMD at the total hip increased 
in the zoledronic acid group by 2.6% at 12 months, 4.7% 
at 24 months, and 5.5% at 36 months and declined in the 
placebo group by 1.0%, 0.7%, and 0.9%, respectively.
The incidence of pyrexia, myalgia and bone pain was 
increased among patients who received zoledronic acid, 
whereas the incidence of serious adverse events was 
comparable in the groups. Similarly, there was no difference 
for the occurrence of serious renal adverse events, arrhythmia 
and atrial ﬁ  brillation. No case of osteonecrosis of the jaw 
was reported.
Discussion
Among postmenopausal women with osteoporosis, zole-
dronic acid administered once a year at 5 mg was associated 
with a 40% reduction in hip fracture risk. In men and women 
receiving the same regimen starting shortly after a ﬁ  rst hip 
fracture, a trend toward a one third reduction in second hip 
fracture incidence has been observed.
Although no direct comparison in head-to-head trials 
examining fracture efﬁ  cacy has been made in comparison 
with other antiresorptive drugs, prescribed orally, the mag-
nitude of the effect looks somewhat larger with zoledronic 
acid. It is also possible to make an indirect comparison 
between placebo-controlled trials, as outlined by Bucher 
and al.31 In indirect comparisons examining risedronate vs 
zoledronic acid and alendronate vs zoledronic acid, there 
was no signiﬁ  cant difference between these drugs for hip 
fracture efﬁ  cacy.32 Several assumptions, however, need to be 
made when those calculations are made. First, the samples 
of patients in the different trials must be drawn from the 
same kind of population. This is not necessarily the case in 
these studies, as inclusion/exclusion criteria differed mark-
edly between these trials. Second, the relative risks have 
to be derived from the intent-to-treat analyses, which was 
the case. Third, the dropouts must be accounted for in the 
trials, which was possible. Rates of compliance, deﬁ  nition 
of outcomes and methodologic quality of the trials can also 
affect the inferences from these indirect comparisons. So, at 
this stage, there is no absolute answer as to whether the hip 
fracture risk reduction observed with zoledronic acid is more 
important than with other bisphosphonates.
The Pivotal Fracture Trial involved both women with 
and without prevalent fracture. This the ﬁ  rst time that a 
reduction in hip fracture risk has been demonstrated in a 
population treated with bisphosphonates including women 
with no prevalent vertebral fracture. So, this compound 
appears to be efﬁ  cacious at various stages of the severity of 
postmenopausal osteoporosis.
The Recurrent Fracture Trial is the ﬁ  rst trial with an anti-
osteoporosis drug that showed a decrease in mortality. This 
reduction was observed after about 16 months of follow-up. 
Given the number of fractures that were avoided by the reduc-
tion of bone fragility, the reduction in fracture risk explained 
2% of the mortality reduction.33 In a post-hoc sub-group Therapeutics and Clinical Risk Management 2009:5 173
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analysis, men experienced a greater mortality benefit, 
with fewer cardiac-related events. Death from pneumonia, 
neoplasms, and cardiovascular disease in patients treated with 
zoledronic acid were reduced, whereas the incidence of these 
diseases was similar to that in the placebo group, suggesting 
that the drug might inﬂ  uence physiologic reserves.
One of the limitations of the ﬁ  rst oral bisphosphonates 
was their daily dosage. Weekly regimens have been devel-
oped later to diminish the treatment annoyance. In a recent 
analysis, 46% of women on a weekly formulation were still 
taking their drug at 1 year, whereas only 33% of those on 
a daily dosage were still on medication.34 Another limita-
tion of oral bisphosphonates is the possibility of digestive 
adverse events such as abdominal pain, dyspepsia and, 
rarely, oesophagitis. Persistence on antiosteoporosis drugs 
is poor, like with most chronic diseases.34 Thus, in a cohort 
of older american women, drug persistence was only 45% 
1 year after starting a treatment for osteoporosis.35 In another 
analysis performed in California, only 25% of women were 
still taking their medication at 1 year.36 In another study 
conducted in North America, raloxifene and bisphosphonates 
were frequently stopped and the main reason for treatment 
interruption was the occurrence of adverse events.37 Anti-
fracture beneﬁ  t, however, improves as much as compliance 
increases.38 The efﬁ  cacy of zoledronic acid on hip fracture 
may be related, at least in part, to its iv administration, 
allowing for a better delivery of the drug at the bone level, 
compared with oral agents.
This effect of yearly intravenous zoledronic acid on hip 
fracture may also be inﬂ  uenced by the quick onset of the 
antiresorptive action. In a randomized, double blind, double-
dummy trial comparing the onset of action of zoledronic acid 
5 mg and alendronate 70 mg in postmenopausal women with 
low BMD,39 the reduction in markers of bone resorption was 
signiﬁ  cantly greater at week one in women on zoledronic 
acid than in those on alendronate. The difference between the 
two drugs waned over time, but a slight difference in favor 
of zoledronic acid remained after 12 weeks.
The quality of trials, ie, their validity, is critical for 
clinical practice and for health care systems who reimburse 
the drugs. The drop-out rate must be low so the intention to 
treat analysis remains reliable, along with sound randomiza-
tion and statistical analysis. A wide spectrum of the disease 
must be enrolled to allow for good generalizability of trial 
results. In the HORIZON Pivotal Fracture trial,28 84% of 
patients remained in active follow-up and 81% received all 
three infusions. For comparison with other major phase III 
osteoporosis trials, 88% of patients were still taking the drug 
after 3 years in the FIT I trial testing alendronate,15 complete 
follow-up data at 3 years were available for only 64% of the 
women in the HIP trial examining risedronate,16 or 64% to 
68% (according to different treatment groups) completed 
the study in the 3-year BONE trial testing the efﬁ  cacy of 
oral ibandronate.18 In the HORIZON Recurrent Fracture 
Trial.29 which was an event-driven trial, 71% of the patients 
completed the trial, but only 3% were lost to follow-up. 
Results from the HORIZON program apply to a large range 
of severity of postmenopausal osteoporosis, because women 
could have osteoporosis with or without prevalent vertebral 
fracture, the ages ranging from 65 to 89. They could have 
already received certain osteoporosis medications, and there 
were few exclusion criteria. Patients in the HORIZON Recur-
rent Fracture Trial had a recent hip fracture.
Patients at risk of hip fracture are generally elderly, 
over 75. So, the tolerability of drugs is essential in this frail 
population. In the HORIZON Pivotal Fracture Trial, 2.3% 
of women had hypocalcemia, deﬁ  ned as serum calcium 
below 2.075 mmol/L, 9 to 11 days after the infusion. These 
episodes were transient and asymptomatic in all cases. In 
the HORIZON Recurrent Fracture Trial, although patients 
were older and more frail, fewer episodes of hypocalcemia 
were observed (0.3%), possibly due to the loading dose of 
vitamin D patients received before their ﬁ  rst infusion. So, 
hypocalcemia appears to be a rare and subclinical event in 
women receiving zoledronic acid. In older patients, however, 
it is probably wise to measure serum dihydroxy-vitamin D 
and to give an adequate vitamin D supplement, including a 
loading dose if judged necessary, to avoid hypocalcemia as 
much as possible.
In the HORIZON Pivotal Fracture Trial, but not in the 
HORIZON Recurrent Fracture Trial, serious atrial ﬁ  brillation 
occurred more frequently in the zoledronic acid group (1.3%) 
than in the placebo group (0.5%, p   0.001). This ﬁ  nding has 
prompted several groups to report data on atrial ﬁ  brillation 
from other bisphosphonates trials. In the FIT trials, a trend was 
observed for the occurrence of serious atrial ﬁ  brillation, with 
a relative hazard of 1.51 (0.97, 2.40).40 In the phase III trials 
of risedronate for osteoporosis, there was no difference in the 
incidence of atrial ﬁ  brillation, stroke, or death related to car-
diovascular disease between the placebo and treated groups.41 
In a population-based case control study in Denmark based 
on medical databases, involving 13,694 patient with atrial 
ﬁ  brillation/ﬂ  utter and 68,470 controls, there was no associa-
tion between use of oral bisphosphonate and the risk of atrial 
ﬁ  brillation/ﬂ  utter.42 In this context of conﬂ  icting data on the 
inﬂ  uence of bisphosphonates on the risk of atrial ﬁ  brillation, Therapeutics and Clinical Risk Management 2009:5 174
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it remains possible that the observation of increased risk in the 
HORIZON Pivotal Fracture Trial is a chance ﬁ  nding induced 
by multiple comparisons. The possibility that this arrhythmia 
might be related to subclinical hypocalcemia and the result-
ing secondary hyperparathyroidism,43 however, points to the 
need for monitoring this potential cardiovascular event when 
zoledronic is marketed worldwide.
One of the concerns with new antiresorptive agents 
is their bone safety, regarding the risk of mineralization 
defects and the risk of over-suppression of bone turnover. 
In the ancillary bone biopsy study of the HORIZON trial, 
there was no mineralization defect.30 All 152 but 1 biopsies 
showed evidence of tetracycline label, indicating preserved 
remodeling capacity. One year after treatment, before the next 
infusion, an increase in serum markers of bone resorption was 
visible, consistent with this preservation of bone remodel-
ing capacity. It is likely that zoledronic acid may be started 
among patients who have already received other bisphos-
phonates. In a randomized double blind double dummy trial, 
conducted in postmenopausal women with low BMD who 
had been previously treated with alendronate for an average 
4 years, patients received either yearly zoledronic acid 5 mg 
or oral weekly alendronate 70 mg over 1 year.44 BMD was 
maintained in both groups, with no signiﬁ  cant difference in 
BMD change between the two groups. In addition, zoledronic 
acid further diminished markers of bone resorption, which 
increased thereafter, suggesting a preserved bone remodeling 
capacity. Thus, there is ample evidence for satisfactory bone 
safety with the use of yearly zoledronic acid over 3 years.
Osteonecrosis of the jaw associated with the use of 
bisphosphonates has been described since 2003. It is deﬁ  ned 
by exposed bone in the maxillofacial region during at least 
8 weeks, in patients previously or currently taking bisphos-
phonates, who did not receive radiotherapy of the maxillofa-
cial region.45 The incidence of osteonecrosis of the jaw among 
patients receiving monthly infusions of pamidronate or zole-
dronic acid to treat malignancy ranges between 1% and 10%. 
In patients taking bisphosphonates for the treatment of Paget’s 
disease of bone or osteoporosis, it seems to be an exceptional 
event, with an incidence of 1/100,000 per patient-years. In 
the HORIZON Pivotal Fracture Trial, there were one case 
in the placebo group and one case in the zoledronic acid 
group. No case of osteonecrosis of the jaw was identiﬁ  ed in 
the HORIZON Recurrent Fracture Trial. Prior studies show 
that the incidence of osteonecrosis of the jaw is proportional 
to the cumulative dose of bisphosphonate, explaining the 
much higher incidence among patients with malignancies 
than those with osteoporosis. It is likely that the incidence of 
osteonecrosis of the jaw that might be observed in patients 
receiving zoledronic acid is comparable to that encountered 
with previous oral bisphosphonates used for osteoporosis. 
The occurrence of this adverse event is certainly related to the 
dose and not to the mode of administration. So, at this stage, 
it has been recommended by the American Society for Bone 
and Mineral Research Task Force45 that patients be informed 
about the risk of osteonecrosis of the jaw, maintain good oral 
hygiene and have regular dental visits. There is no contra-
indication to dental implant placement. Current evidence 
supports the same recommendations for annual zoledronic 
acid as for older oral bisphosphonate therapies.
Conclusion
Yearly intravenous zoledronic acid 5 mg is an effective 
treatment to reduce the incidence of hip fracture among 
postmenopausal osteoporotic women. A trend toward a 
second hip fracture risk reduction has also been observed 
in patients with a ﬁ  rst hip fracture. This treatment has been 
well tolerated in clinical trials.
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